Quanterix earnings release, May 6, 2026
Quanterix Releases Financial Results for the First Quarter of 2026
Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities
Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness
BILLERICA,
Mass. – May 6, 2026
-
Quanterix Corporation
(NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026.
“We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition,” said Everett Cunningham, President & CEO of Quanterix. “As part of this process, we are focusing our investment into areas that will benefit our commercial effectiveness and drive improved operating results in 2026 and beyond. Additionally, our Alzheimer’s diagnostics business continues its rapid growth with several key milestones expected in the second half of this year, including the completion of three clinical utility studies and a decision from the FDA on our 510(k) application.”
First Quarter Financial Highlights
• Revenue of $36.4 million, an increase of 20% compared to $30.3 million in the prior year.
• GAAP gross margin of 42.7%, as compared to 48.9% in the prior year. Adjusted gross margin (non-GAAP) of 50.9% as compared to 49.7% in the prior year. Prior year margins are updated to reflect a change in accounting policy in Q1’26 related to shipping and handling costs. Shipping and handling costs for product sales are now recorded in cost of product revenue in the Company’s GAAP financials.
• Adjusted EBITDA (non-GAAP) loss of $9.8 million, compared to a loss of $11.3 million in the prior year.
• The Company ended the first quarter with $102.6 million of cash, cash equivalents, marketable securities, and restricted cash. Adjusted cash usage, after accounting for one-time deal and employee separation costs of $4.2 million, was $14.7 million in the first quarter, an increase from the fourth quarter of 2025 driven by seasonally higher payments.
Operational and Business Highlights
• Announced a collaboration with Tempus AI to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease. Through the agreement, Tempus AI will build a care gap program for Alzheimer’s disease blood-based biomarker testing, with Quanterix’s LucentAD® Complete multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform.
• Announced a diagnostics collaboration with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the collaboration, Life Line Screening will offer Quanterix’s Lucent Diagnostics non-invasive blood-based biomarker test for p-tau 217 nationally.
• Selected as a Co-Investigator institution in the PD-BUILD program, part of the Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network (CRN) 2026 expansion, supported by The Michael J. Fox Foundation (MJFF). This multi-year grant brings together leading institutions across academia and industry to develop and deploy high-quality biomarker tools aimed at enabling earlier detection, improved patient stratification, and more effective monitoring of Parkinson’s disease in clinical research.
• Quanterix’s newly launched PhenoCode™ Discovery IO60 panel won silver at the Edison Awards. This award-winning product enables simultaneous visualization of 60 key markers across immune cell types, checkpoints, and tumor-specific pathways.
• Simoa® Ultra-Sensitive Immunoassay launched 3 new assays - mammalian GFAP advantage plus, IL12p70 advantage plus and IL17F advantage plus.
• The Accelerator Service Lab announced two new ADC lung cancer panels for Akoya PhenoImager™ HT at the American Association for Cancer Research(AACR) 2026 annual meeting. Building on the ADC breast cancer panel debuted at the AACR 2025 annual meeting, both panels are available today as a fully managed service.
2026 Business Outlook
Quanterix is reaffirming its guidance for 2026. The Company expects revenues of $169 to $174 million, which assumes no underlying improvement in the academic or pharmaceutical end markets. Quanterix anticipates GAAP gross margin of 41% to 45%, and adjusted gross margin (non-GAAP) of 49% to 53%.
In the first quarter, Quanterix changed its accounting policy for classifying shipping and handling costs for product sales to record them within gross margin. Historically, these costs were recorded in selling, general and administrative expenses. This reclassification is reflected in the Company’s GAAP guidance range, but there is no change to the non-GAAP margin expectation.
Quanterix continues to anticipate achieving cash flow breakeven in the second half of the year and expects to end the year with cash in the range of $100M, and no debt.
Conference Call
In conjunction with this announcement, the Company will host a conference call on May 6, 2026, at 4:30 PM ET. The dial-in number for USA & Canada is Toll-Free (800) 715-9871 or (646) 307-1963 and the conference ID is 8523507.
Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at https://ir.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.
About Quanterix... (truncated)tions, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,450 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.
Financial statements
Income Statement
Three Months Ended March 31, — (amounts in thousands, except per share data, unaudited)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Revenues: | Product revenue | 25,479 | 20,739 |
| Revenues: | Service and other revenue | 10,376 | 8,823 |
| Revenues: | Collaboration and license revenue | 560 | 771 |
| Revenues: | Total revenues | 36,415 | 30,333 |
| Costs of goods sold and services: | Cost of product revenue | 15,140 | 11,341 |
| Costs of goods sold and services: | Cost of service and other revenue | 5,709 | 4,154 |
| Costs of goods sold and services: | Total costs of goods sold and services | 20,849 | 15,495 |
| Costs of goods sold and services: | Gross profit | 15,566 | 14,838 |
| Operating expenses: | Research and development | 7,323 | 10,036 |
| Operating expenses: | Selling, general and administrative | 29,770 | 31,168 |
| Operating expenses: | Impairment | 19,835 | |
| Operating expenses: | Total operating expenses | 56,928 | 41,204 |
| Operating expenses: | Loss from operations | -41,362 | -26,366 |
| Other income (expense), net: | Interest income | 892 | 3,267 |
| Other income (expense), net: | Change in fair value of contingent liabilities | 1,501 | -379 |
| Other income (expense), net: | Other income, net | 21,421 | 61 |
| Other income (expense), net: | Loss before income taxes | -17,548 | -23,417 |
| Other income (expense), net: | Income tax benefit | 7 | 2,913 |
| Other income (expense), net: | Net loss | -17,541 | -20,504 |
| Other income (expense), net: | Net loss per common share, basic and diluted | -0.37 | -0.53 |
| Other income (expense), net: | Weighted-average common shares outstanding, basic and diluted | 46,979 | 38,718 |
Income Statement
Three Months Ended March 31, — (Unaudited, in thousands except percentages)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | |
|---|---|---|
| Net loss | -17,541 | -20,504 |
| Interest income | -892 | -3,267 |
| Income tax expense (benefit) | -7 | -2,913 |
| Depreciation and amortization | 5,603 | 2,188 |
| Stock-based compensation expense (1) | 4,177 | 5,462 |
| Acquisition and integration related costs (2) | 1,152 | 3,578 |
| Earnout recorded as compensation expense (3) | 3,744 | |
| Changes in contingent liabilities (4) | -1,501 | 379 |
| Impairment and employee separation costs (5) | 20,787 | |
| Income from contract termination (6) | -21,596 | |
| Adjusted EBITDA (non-GAAP) | -9,818 | -11,333 |
| Total revenues | 36,415 | 30,333 |
| Adjusted EBITDA margin (non-GAAP) (adjusted EBITDA as a % of revenue) | -27 | -37.4 |
Income Statement
Three Months Ended March 31, — (Unaudited, in thousands, except percentages)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | |
|---|---|---|
| Gross profit | 15,566 | 14,838 |
| Purchase accounting impact on inventory and property and equipment (1) | 199 | |
| Amortization of acquired intangible assets (2) | 2,772 | 227 |
| Adjusted gross profit (non-GAAP) | 18,537 | 15,065 |
| Total revenues | 36,415 | 30,333 |
| Gross margin (gross profit as % of total revenues) | 42.7% | 48.9% |
| Adjusted gross margin (non-GAAP) (adjusted gross profit as % of total revenues) | 50.9% | 49.7% |
| Total operating expenses | 56,928 | 41,204 |
| Purchase accounting impact on property and equipment (1) | -223 | |
| Amortization of acquired intangible assets (2) | -77 | |
| Acquisition and integration related costs (3) | -1,152 | -3,578 |
| Earnout recorded as compensation expense (4) | -3,744 | |
| Impairment and employee separation costs (5) | -20,787 | |
| Adjusted total operating expenses (non-GAAP) | 34,689 | 33,882 |
| Loss from operations | -41,362 | -26,366 |
| Purchase accounting impact on inventory and property and equipment (1) | 422 | |
| Amortization of acquired intangible assets (2) | 2,849 | 227 |
| Acquisition and integration related costs (3) | 1,152 | 3,578 |
| Earnout recorded as compensation expense (4) | 3,744 | |
| Impairment and employee separation costs (5) | 20,787 | |
| Adjusted loss from operations (non-GAAP) | -16,152 | -18,817 |
Balance Sheet
March 31, 2026 — (amounts in thousands, except per share data, unaudited)
| March 31, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 36,182 | 29,839 |
| Current assets: | Marketable securities | 63,083 | 88,393 |
| Current assets: | Accounts receivable, net of allowance for expected credit losses | 26,776 | 29,972 |
| Current assets: | Inventory | 50,959 | 54,763 |
| Current assets: | Prepaid expenses and other current assets | 8,725 | 9,290 |
| Current assets: | Total current assets | 185,725 | 212,257 |
| Current assets: | Restricted cash | 3,344 | 3,341 |
| Current assets: | Property and equipment, net | 21,369 | 23,672 |
| Current assets: | Intangible assets, net | 109,161 | 131,787 |
| Current assets: | Goodwill | 26,710 | 26,376 |
| Current assets: | Operating lease right-of-use assets | 15,861 | 16,664 |
| Current assets: | Other non-current assets | 4,502 | 4,669 |
| Current assets: | Total assets | 366,672 | 418,766 |
| Current liabilities: | Accounts payable | 8,657 | 13,568 |
| Current liabilities: | Accrued compensation and benefits | 9,850 | 14,979 |
| Current liabilities: | Accrued expenses and other current liabilities | 8,275 | 17,571 |
| Current liabilities: | Deferred revenue | 15,190 | 20,728 |
| Current liabilities: | Operating lease liabilities | 7,933 | 7,916 |
| Current liabilities: | Total current liabilities | 49,905 | 74,762 |
| Current liabilities: | Deferred revenue, net of current portion | 2,795 | 5,830 |
| Current liabilities: | Operating lease liabilities, net of current portion | 27,403 | 29,323 |
| Current liabilities: | Non-current portion of contingent liabilities | 3,547 | 5,024 |
| Current liabilities: | Other non-current liabilities | 883 | 8,097 |
| Current liabilities: | Total liabilities | 84,533 | 123,036 |
| Current liabilities: | Total stockholders’ equity | 282,139 | 295,730 |
| Current liabilities: | Total liabilities and stockholders’ equity | 366,672 | 418,766 |
Full release
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix’s future business outlook, operations, strategy and financial performance, including statements related to our expectations about consistent profitable revenue growth and achieving cash flow breakeven performance, the development and commercialization of our products, the benefits and synergies we may realize from the acquisition of Akoya Biosciences Inc., and under the header “2026 Business Outlook.”. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix’s future business, operations, strategy and financial performance: risks related to the impact of changes in U.S. government policies, including impacts of tariffs and reductions in federal research funding; risks associated with the anticipated timing for launch of, and features of, Quanterix’s next-generation instruments to upgrade its existing platforms; risks related to Quanterix’s ability to improve existing diagnostics and develop new diagnostic tests and tools; risks related to Quanterix’s ability to successfully penetrate the diagnostics market; risks related to Quanterix’s ability to retain and expand its customer base and achieve sufficient market acceptance of its products; risks related to the ability of Quanterix’s contract manufacturers and suppliers to reliably and consistently manufacture and supply our instruments; risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisitions of Emission, Inc. and Akoya Biosciences Inc.; risk that integrating Quanterix’s business with that of Akoya could be more difficult, costly or time-consuming than expected; risks that Quanterix’s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to Quanterix’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures; and risks related to defects or other quality issues in
Quanterix’s products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation. Additional factors that could cause results to differ materially from those described above can be found in the periodic reports filed by Quanterix with the SEC, including the “Risk Factors” sections contained therein, which are available on the SEC’s website at www.sec.gov.
All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
Financial Highlights